Inovio Pharmaceuticals
INO
84 hedge funds and large institutions have $138M invested in Inovio Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 31 increasing their positions, 20 reducing their positions, and 16 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 20
50% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 16
11% more funds holding
Funds holding: 76 → 84 (+8)
10% more capital invested
Capital invested by funds: $125M → $138M (+$12.9M)
0.33% more ownership
Funds ownership: 1.6% → 1.93% (+0.33%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
39% less call options, than puts
Call options by funds: $4.24M | Put options by funds: $6.92M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$7.76M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$5.14M |
| 3 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
+$3.69M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$2.6M |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$2.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCIM
TIAA CREF Investment Management
New York
|
-$4.17M |
| 2 |
BG
BlackRock Group
London,
United Kingdom
|
-$1.51M |
| 3 |
Goldman Sachs
New York
|
-$1.12M |
| 4 |
Jane Street
New York
|
-$843K |
| 5 |
Millennium Management
New York
|
-$665K |
INO Hedge Fund Activity: Q3 2014 in Review
84 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q3 2014, worth a combined $138M — up 10% from $125M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new INO positions and 16 closed out — a net gain of 8 holders — while 31 added to existing stakes and 20 trimmed.
The largest buyer was Putnam Investments, opening a new position worth an estimated $7.76M. The largest seller was TIAA CREF Investment Management, cutting an estimated $4.17M.
- 84 institutional investors held Inovio Pharmaceuticals (INO) as of Q3 2014, up from 76 in Q2 2014.
- Funds reported $138M of Inovio Pharmaceuticals stock for Q3 2014, up 10% quarter-over-quarter.
- 24 funds opened new Inovio Pharmaceuticals positions in Q3 2014 and 16 closed out, a net change of +8 holders.
- The largest Inovio Pharmaceuticals buyer in Q3 2014 was Putnam Investments, an estimated $7.76M added.
- The largest Inovio Pharmaceuticals seller in Q3 2014 was TIAA CREF Investment Management, an estimated $4.17M sold.
Based on aggregated 13F filings for Q3 2014.